Proinflammatory signals promote prostate tumorigenesis and progression, but their origins and downstream effects remain unclear. We recently demonstrated that the expression of an innate immune receptor, TLR9, by prostate cancer cells is critical for their tumorpropagating potential. We investigated whether cancer cell-intrinsic TLR9 signaling alters composition of the prostate tumor microenvironment. We generated Ras/ Myc (RM9) and Myc-driven (Myc-CaP) 
Introduction
Prostate cancer is the third most often diagnosed cancer in the United States; it is estimated that ;13% of men will have prostate cancer during their lifetime [1] . Growing evidence suggests that chronic inflammation raises the risk of development of high-grade prostate cancer [2] . Inflammatory signals play pivotal roles in oncogenic transformation and immunosuppressive microenvironment formation in cancer [3, 4] . Damaged cells from tissue injury by radiation therapy release endogenous damage-associated molecular patterns, including mitochondrial DNA, which can be recognized by TLR9 and activate immune responses [5] . TLR9 is commonly expressed by tumorassociated myeloid cells and is responsible for tumor revascularization and recurrence after local radiation therapy [6] . TLR9 can also be upregulated by cancer cells in hematologic malignancies and in certain solid tumors, such as CRPCs [7] . We have shown that prostate cancer cell-intrinsic TLR9 signaling promotes tumor-propagating potential via NF-kB/RELA and STAT3 transcription factors in human prostate cancer xenografts [8] . NF-kB/RELA and STAT3 co-regulated expression of several cancer stem cell-related genes at least partly explains the increased tumor-propagating potential of prostate cancer cells. The potential effect of prostate cancer cell-intrinsic TLR9 signaling on the TME remains unexplored.
LIF, a member of IL-6 family cytokines, is a functionally pleiotropic signaling mediator. LIF signaling uses a heterodimer of the specific LIFR with a shared IL-6Rb subunit (gp130) to activate downstream signaling through the Jak/STAT, MAPK, and PI3K signaling pathways [9, 10] . High plasma levels of LIF have been observed in various types of human solid tumors, including breast, skin, and colorectal cancer, and correlates with increased chemo-and radioresistance [10] . LIF expression is induced by hypoxia-inducible factor 2a [11] and negatively regulates p53 by activating the proteolytic pathway in colorectal cancers [12] . However, the role of LIF in modulating crosstalk and the immunosuppressive signaling network in the microenvironment of solid tumors, such as those in prostate cancer, remains unknown. In the current study, we investigated whether and how inflammatory signaling induced by TLR9 expression in prostate cancer cells affects composition and the immunosuppressive potential of the TME.
MATERIALS AND METHODS

Cells
The RM9 cell line was kindly provided by Dr. T. Thompson (University of Texas MD Anderson Cancer Center, Houston, TX, USA) and Myc-CaP cells were purchased from ATCC (Manassas, VA, USA). All cells were authenticated and verified as free from contamination by other cell types (Biosynthesis, Lewisville, TX, USA). Cell lines with tetracycline-inducible TLR9 expression were generated with the ViraPower HiPerform/T-Rex/Gateway system (Thermo Fisher Scientific, Waltham, MA, USA), according to the manufacturer's protocol. In brief, full-length mouse TLR9 cDNA was cloned into a lentiviral vector pLenti6.3/TO/V5-DEST (LV-TLR9). LV-TLR9 and LV-Tet Repressor were cotransduced in RM9 or Myc-CaP cells, followed by selection in blasticidin (10 mg/ml)-and geneticin (100 mg/ml)-supplemented media. The PC3-shTLR9, PC3-Mock, LNCaP-TLR9, and LNCaP-Mock cells were generated as described elsewhere [13] .
Animal studies
Mouse care and experimental procedures were performed in pathogen-free conditions, according to protocols approved by the Institutional Animal Care and Use Committee (IACUC) of COH. RM9-TetOn-Tlr9 (RM9-Tlr9 ) were implanted subcutaneously in the abdomen of male C57/BL6 [National Cancer Institute (NCI), Frederick, MD, USA] and FBV mice (NCI), respectively. Mice with established tumors were injected retro-orbitally every other day with tetracycline (2 mg). For MDSC depletion, 40 mg of anti-Gr1 antibody (RB6-8C5) or Rat-IgG was injected intratumorally every 3 d. For LIF neutralization, 10 mg of a goat polyclonal LIF-neutralizing antibody (AF449; R&D Systems, Minneapolis, MN, USA) or goat IgG was injected intratumorally every other day. For TLR9-targeted STAT3 inhibition, CpG-STAT3dODN or control CpG-scrODN (5 mg/kg) was injected intratumorally every other day. Tumor volume was measured with calipers. For biodistribution studies, CpG-STAT3dODN
Cy3 (5 mg/kg) was injected intratumorally. Mice were euthanized after 3 h, and flow cytometry was used to analyze the CpG-STAT3dODN uptake by tumor-infiltrating immune cells. All oligonucleotide reagents were synthesized at the DNA/RNA Synthesis Core at COH.
Flow cytometry
For the analysis of tumor-associated immune cells, we prepared single-cell suspensions from whole tumors using mechanical dispersion and short DNase I/ collagenase IV treatment (20 min/37°C 
Patient-derived blood specimens
Blood samples from patients with high-risk localized prostate cancer or mCRPC had been collected within two clinical studies (IRB nos. 11020 and 13141, respectively), whereas healthy subject specimens were obtained from the blood transfusion center (IRB no. 13378) at COH. Samples were processed to isolate PBMCs and plasma [8] . Plasma and PBMCs were collected separately and stored in 280°C or liquid nitrogen, respectively. The protocols and the relevant informed consent were approved by the institutional scientific review committee, the data safety monitoring board, and the IRB at COH. All patients enrolled provided written informed consent, and the study was conducted in accordance with the amended Declaration of Helsinki and the International Conference on Harmonization Guidelines.
MDSC isolation and functional analysis
Splenic MDSCs from tumor-bearing mice were sorted on the FACSAriaIII Cell Sorter (BD Biosciences). T cells were negatively selected from spleens of naive mice with the MagniSort Mouse T cell Enrichment Kit (eBioscience) and then labeled with CFSE (Thermo Fisher Scientific 
Real-time qPCR
Tumors were harvested and a single-cell suspension was developed as described above. 
Western blot analysis
To detect LIF protein levels in human PC3-Mock, PC3-shTLR9, LNCaP-Mock, and LNCaP-TLR9 prostate cancer cells, the cells were treated with GolgiStop (BD Biosciences) for 6 h before harvesting. For detection of LIF in mouse tumor, CD45 2 cells were enriched. Total cellular lysates were prepared as reported [13] and analyzed by using antibodies specific to LIF (Abcam Inc., Cambridge, MA, USA) and b-actin (Sigma-Aldrich, St. Louis, MO, USA).
Prognostic outcome gene expression analysis
The correlation of TLR9 vs. IL-6 or LIF gene expression was assessed with Pearson's correlation test based on the RNAseq gene expression data derived from the provisional data set, in whole or in part based on data generated by TCGA Research Network (http://cancergenome.nih.gov/; NCI), with a set of 542 tissue specimens (490 tumor and 52 normal tissue samples). R Bioconductor statistical software was used for the meta-analysis to correlate genotypes with clinicopathologic outcomes. The high-throughput RNA sequencing data were downloaded from the UCSC Cancer Genome Browser (https://genome-cancer.ucsc.edu/unc.edu_PRAD.IlluminaHiSeq_RNA-SeqV2.Level_3.1.14.0.tar.gz). The associated clinical data were downloaded from TCGA Data Portal (https://tcga-data.nci.nih.gov/tcga/).
Statistical analysis
The unpaired t test was used to calculate the 2-tailed P value to estimate the statistical significance of differences between 2 experimental groups, unless otherwise indicated. One-or 2-way ANOVA and the Bonferroni post hoc test were applied to assess the statistical significance of differences between multiple treatment groups or patients from different stages and healthy donors. Data were analyzed with Prism ver. 6.0 software (GraphPad Software, La Jolla, CA, USA).
RESULTS
Prostate cancer cell-intrinsic TLR9 upregulation accelerates tumor progression through PMN-MDSC recruitment
We recently demonstrated that the activation of TLR9 signaling in prostate cancer cells induces expression of tumorigenic cytokines and growth factors, such as IL-6 and vascular endothelial growth factor [13] . These mediators may also increase the immunosuppressive activity of the TME by stimulating the activity of STAT3, especially in myeloid immune cells. To verify this hypothesis, we used a tetracycline-inducible expression system (TetOn) for temporal control of Tlr9 expression, generating two stably transduced prostate cancer cell types: RM9-TetOn-Tlr9 (RM9-Tlr9
ON
) and Myc-CaP-TetOn-Tlr9 (Myc-CaP-Tlr9 ON ). Both types of cancer cells were implanted subcutaneously in mice. After tumors were established, the Tlr9 expression was induced by injections every other day of 2 mg tetracycline or vehicle only (PBS). Systemic administration of tetracycline upregulated Tlr9 expression in both RM9-Tlr9 1A) and Myc-CaP-Tlr9 ON (Fig. 1C ) tumors, compared with tumors from vehicle-treated mice. Even though both RM9 and Myc-CaP cells formed aggressive and rapidly growing tumors, the induction of TLR9 expression significantly enhanced tumor growth kinetics ( Fig. 1B and D) . Next, we assessed whether the elevated levels of TLR9 in cancer cells affect the composition of the TME. The infiltration of various myeloid immune cell subsets was analyzed by flow cytometry in RM9-Tlr9
ON and Myc-CAP- Fig. 2 ). The Gr1-depletion resulted in a strong reduction of TLR9-induced tumor growth in tetracycline-treated mice to the level of vehicletreated mice (Fig. 1H) . These results underscore the important role of Gr1 + myeloid cells, including MDSCs, in promoting TLR9-enhanced prostate tumor progression.
TLR9 upregulation in cancer cells augments the immunosuppressive potential of PMN-MDSCs
To evaluate whether TLR9-expressing tumors modulate the function of tumor-associated PMN-MDSCs we examined the expression of STAT3 and its downstream targets, which positively regulate the immunosuppressive functions of MDSCs: S100A8, ON tumor-bearing mice treated with PBS or tetracycline were injected intratumorally with either 40 mg of anti-Gr1 antibody or control rat IgG. Tumor growth kinetics was monitored (n $ 5 per group); data are means 6 SEM. *P , 0.05; **P , 0.01. S100A9, and C/EBPb. Tetracycline treatment significantly induced gene expression of all 4 MDSC-related biomarkers, specifically in PMN-MDSCs, but not in M-MDSCs isolated from RM9-Tlr9
ON tumors ( Fig. 2A) . Our further flow cytometric analysis found that TLR9 upregulation in cancer cells caused a significant increase in the percentage of tumor-associated PMNMDSCs with activated STAT3 (STAT3P: tyrosine 705-phosphorylated STAT3) from average 12-40% (Fig. 2B) . The percentage of pSTAT3 + M-MDSCs also increased after TLR9
induction from an average of 5-20%. STAT3 is known to directly drive expression of 2 key effector molecules for MDSC functions, arginase-1 and IL-10, maintaining an immunosuppressive microenvironment in many types of human cancers [16, 17] and also in mouse tumor models [17] [18] [19] [20] [21] . Corresponding to the pSTAT3 upregulation pattern, we found higher basal and TLR9-upregulated levels of arginase-1 in tumorassociated PMN-MDSCs than in M-MDSCs, compared with controls (Fig. 2B) . The increased Arg-1 mRNA levels and higher enzymatic arginase-1 activity were also detected in the total splenic Gr1 + population in the tetracycline-treated RM9-Tlr9
ON tumor-bearing mice (Supplemental Fig. 3 ). In contrast, both PMN-and M-MDSCs expressed high basal levels of IL-10, which were only weakly upregulated in TLR9-overexpressing tumors (Fig. 2B) . Finally, we verified whether these phenotypic changes would translate into modification of immunosuppressive activity of both MDSC subsets ex vivo. Both splenic PMN-and M-MDSCs were sorted from either tetracycline-or PBS-treated RM9-Tlr9
ON tumor-bearing mice and cocultured with CD3/28-activated T cells. The 2 MDSC populations differed in basal immunosuppressive activity, which was higher in PMN-than M-MDSCs. Correspondingly, PMN-MDSCs in the prostate TME showed increased activity of STAT3, a known master regulator of immunosuppression [3, 4] . A possible explanation for the weak suppressive activity of M-MDSCs is the heterogeneity of CD11b + Ly6G LO Ly6C HI population, which are known to include more differentiated and less immunosuppressive myeloid cell populations [22, 23] . Nonetheless, both tumor infiltrating MDSC subsets became more immunosuppressive after TLR9 induction in cancer cells (Fig. 2C) . T cell proliferation was inhibited by more than 90% by PMN-MDSCs and by ;40% by M-MDSCs isolated from TLR9 HI tumors. The results suggest that cancer cell-intrinsic TLR9 signaling not only increases tumor infiltration by PMN-MDSCs, but also augments tolerogenic activity of myeloid suppressor cells.
TLR9 upregulation is associated with LIF expression in human and mouse prostate cancers
Multiple cytokines and growth factors secreted by cancer cells can potentially activate STAT3 in tumor-associated myeloid cells, with a prominent role of IL-6 in prostate tumor progression [4, 13, 24] . To identify the potential STAT3 activator secreted by TLR9-expressing cancer cells, we compared cytokine/growth factor expression profiles in prostate cancer cells after TLR9 upregulation in vivo (Supplemental Fig. 4 ). The expression levels of 42 of 84 genes tested were altered more than 2-fold as a result of the TLR9 induction. Thirty-six downregulated mRNAs included proinflammatory mediators, such as Ifna2, Il1a, il1b, Cxcl5, and Tnf. Among the upregulated gene targets was LIF, a member of an IL-6-type cytokine family and a potent activator of Jak/STAT3 signaling [9] . In fact, gene expression analysis in RM9 and previously published whole-genome expression analysis of human TLR9 + PC3 cells found that Lif expression is significantly higher than other tested IL-6 cytokines, such as Il6, Il11, Osm, or Cntf (Fig.  3A ) [13] . Similarly, gene expression analysis of 490 specimens from patients with prostate cancer derived from TCGA datasets revealed a significantly higher level of LIF expression compared to that of IL-6 or any other IL-6 family cytokine (Fig. 3B ). Further analysis confirmed that mRNA level of Lif was upregulated in both RM9-Tlr9 ON and Myc-CaP-Tlr9 ON tumors in vivo after tetracycline treatment compared with that in PBStreated control tumors (Fig. 3C ). Consistently, the protein level of Lif was increased in RM9-Tlr9 ON tumor after tetracycline treatment in vivo (Fig. 3D) . Furthermore, we found strong correlation between mRNA levels of Tlr9 and Lif in RM9-Tlr9
ON tumors from these in vivo studies, whereas the correlation between Tlr9 and Il6 expression was not significant (Fig. 3E) . To elucidate the mechanism of TLR9-mediated regulation of LIF expression, we analyzed the sequence of the Lif promoter for putative transcription factor binding sites with MotifMap opensource software (http://motifmap.ics.uci.edu/; University of California, Irvine, CA, USA). We identified a consensus element for NF-kB, one of the crucial mediators of downstream TLR9 signaling and transcriptional partners of STAT3 [3] . Using chromatin immunoprecipitation with NF-kB-specific antibodies, we next confirmed a direct binding of this transcription factor to the Lif promoter. The tetracycline-mediated upregulation of TLR9 expression in RM9 cancer cells enhanced .4-fold the NFkB binding to the Lif promoter compared to the control PBStreated tumors (Fig. 3F) . Although the consensus site for STAT3 was not identified by the in silico analysis, the chromatin immunoprecipitation assay found STAT3 constitutively bound to the Lif promoter with only a weak increase upon TLR9 induction. The data suggest that LIF expression in prostate cancer cells is regulated by TLR9 signaling in an NF-kBdependent manner.
To assess the relevance of our findings to human prostate cancers, we used previously described prostate cancer cells stably expressing TLR9 at high (PC3-Mock and LNCaP-TLR9) or low (PC3-shRNA and LNCaP-Mock) levels [13] . As ON tumor-bearing mice after treatment with PBS (n = 3) or tetracycline (n = 3). The mRNA expression levels of S100a8, S100a9, Cebpb, and Stat3 were assessed with real-time qPCR. (B) Levels of tyrosine-pSTAT3, arginase-1 (Arg-1), and IL-10 were analyzed in tumorinfiltrating PMN-and M-MDSCs from PBS-or tetracycline-treated Myc-CaP-Tlr9 ON tumors by flow cytometry (n = 6/group). (C) PMN-and M-MDSCs were sorted from spleens of PBS-or tetracycline-treated mice bearing RM9-Tlr9
ON tumors (n = 3/group). CFSE-labeled CD3 + T cells were activated with CD3/CD28 microbeads and cocultured for 3 d with PMN-or M-MDSCs (MDSC:T cell ratio = 1:2). Cells were harvested and T cell proliferation was analyzed by CFSE dilution assay and flow cytometry. Data are means 6 SEM. *P , 0.05; **P , 0.01; ***P , 0.001; ****P , 0.0001. 2 tumor cells isolated from a single Myc-CAP-Tlr9 ON tumor-bearing mouse after PBS (black) or tetracycline treatment (red). (F) The association of NF-kB and Stat3 at the putative NF-kB-binding site were examined by ChIP assay followed by RT-qPCR using primers encompassing 2200 upstream from the transcription start site. Transcription factor binding sites were predicted at the Lif promoter region (n = 3) with MotifMap. Data are means 6 SEM. (G-I) PC3 (TLR9 + ) and LNCAP (TLR9 2 ) prostate cancer cells were genetically modified to alter basal levels of TLR9, creating PC3-mock/PC3-shTLR9 and LNCaP-mock/LNCaP-hTLR9, as described elsewhere [13] . Shown is the effect of LIF expression on the mRNA levels by qPCR (G), protein levels by Western blot analysis (H), and the concentration of LIF in cell culture supernatant by ELISA (I). Data are means 6 SEM (n = 3). (J) The correlation between TLR9 and LIF expression (r = 0.32; P = 8.88 3 10 215 ), as well as between TLR9 and IL-6 expression (r = 0.22; P = 2.17 3 10 214 ),
as assessed with a TCGA dataset from 490 patients with prostate cancer. *P , 0.05; **P , 0.01; ***P , 0.001; ****P , 0.0001. correlation between mRNA expression of TLR9 and LIF (r = 0.32; P = 8.88 3 10 215 ) and to lesser extent between TLR9
and IL6 (r = 0.22; P = 2.17 3 10 214 ).
Targeting LIF signaling inhibits PMN-MDSC accumulation and prostate tumor progression
Results of our in vitro and in vivo studies suggest that LIF mediates crosstalk between TLR9 + cancer cells and the population of myeloid suppressor cells in the TME. To verify this hypothesis, we performed antibody-mediated neutralization experiments in RM9-Tlr9 ON tumor-bearing mice. Mice were treated with tetracycline, to induce TLR9 expression in cancer cells, while receiving intratumoral injections of LIFspecific antibodies or control IgG every other day. Local LIF neutralization reduced tumor growth and resulted in a tumor mass decreased by half at the end of the experiment (Fig. 4A) .
To characterize the myeloid cell compartment, we harvested tumors of comparable volumes (300-400 mm 3 ). As analyzed using flow cytometry, LIF neutralization in the TME reduced by more than half the percentage of tumor-infiltrating PMN-MDSCs, whereas M-MDSC accumulation was not affected (Fig. 4B ). In addition, STAT3 activity, the expression of arginase-1 and, to a lesser extent, IL-10 were significantly reduced in PMN-MDSCs (Fig. 4C) , thereby reversing the effect of TLR9 upregulation (Fig. 4B) . The results indicate that LIF can promote growth of TLR9-expressing prostate tumors, which correlates with the selective accumulation of PMN-MDSCs.
LIF/LIFR signaling promotes immunosuppressive activity of PMN-MDSCs in patients with prostate cancer
To validate our results in the context of human prostate cancers, we first evaluated LIF plasma levels comparing blood samples collected from healthy donors and patients with localized or CRPC. When compared to healthy subjects, plasma samples from both localized and metastatic prostate cancers showed significantly elevated levels of LIF, without a significant difference between the 2 groups of patients (Fig.  5A) . We have demonstrated that PMN-MDSCs rather than M-MDSCs are the dominant myeloid suppressor cell populations in the circulation of patients with prostate cancer [8] .
The immunosuppressive activity of PMN-MDSCs relies on STAT3 activity to drive the downstream expression of the ARG1 [16] . Thus, we examined whether LIF can stimulate STAT3 signaling in both MDSC populations. The initial flow cytometric analysis of PBMCs of patients with prostate cancer indicated that LIFR was in fact preferentially expressed on the surface of PMN-MDSCs (HLA-DR 2 CD14 2 CD15 + ) and only at low levels on M-MDSCs (HLA-DR 2 CD14 + CD15 2 ), but it was absent on monocytes (HLA-DR + CD14 + ) (Fig. 5B) . Consistent with these observations, in vitro LIF stimulation significantly
induced STAT3 activity in all tested PMN-MDSCs, but only in part of the M-MDSCs tested and not in monocytes (Fig. 5C ). Previous studies established conditions for in vitro generation of MDSCs with the use of GM-CSF stimulation in combination with various tumorigenic cytokines, with the most potent T cell suppression activity resulting from the GM-CSF/IL-6 coculture [25] . Given that GM-CSF was one of the top signaling mediators identified by our initial qPCR array analysis in addition to LIF (Supplemental Fig. 4) , we examined the long-term in vitro effect of these factors on functional MDSC differentiation. Human CD15 + myeloid cells were enriched PBMCs from patients with prostate cancer and were cultured in the presence of GM-CSF or LIF alone or GM-CSF/LIF or GM-CSF/IL-6 combinations for 2 d. The pretreated CD15 + myeloid cells were then cocultured with activated allogeneic T cells from healthy donors. As shown in Fig. 5D , both GM-CSF/LIF and GM-CSF/ IL-6 coculture resulted in generation of CD15 + myeloid cells with the maximum immunosuppressive effect on T cell proliferation.
TLR9/LIF/STAT3 signaling axis as a target for prostate cancer immunotherapy
We recently generated a strategy to deliver oligonucleotide therapeutics, such as small interfering RNA or dODN, into the TLR9 + human and mouse myeloid cells as conjugates with the TLR9 ligands CpG ODNs [26] . Human prostate cancerassociated PMN-MDSCs express high levels of TLR9, compared to M-MDSCs or TLR9
2 monocytes, and therefore it is feasible to use CpG conjugates for targeting this elusive population (Fig. 6A ) [8] . We recently developed a second-generation CpG-STAT3dODN inhibitor that potently inhibits transcriptional activity of STAT3 in myeloid cells [26] . When tested in vitro with flow cytometry, the fluorescence-labeled CpGSTAT3dODN Cy3 was efficiently internalized by most prostate cancer-associated PMN-MDSCs within 1 h of incubation, but less effectively by M-MDSCs and monocytes (Fig. 6B) . Next, we enriched CD15 + granulocytic cells from the peripheral blood of patients with mCRPCs. As demonstrated before, these cells were PMN-MDSCs [8] . CD15 + cells were preincubated with CpG-STAT3dODN, control CpG-scrODN, or PBS and then coincubated with activated allogeneic T cells for the last 3 d. CpG-STAT3dODN, but not control oligonucleotides, attenuated the inhibitory effect of CD15 + myeloid cells on T cell proliferation (Fig. 6C) . These results underscore the therapeutic relevance of targeting STAT3 activity in human myeloid suppressor cells.
Finally, we assessed the antitumor activity of CpGSTAT3dODN in syngeneic mouse RM9 prostate tumors in vivo. As verified by the biodistribution studies using fluorescence-labeled CpG-STAT3dODN
Cy3 , intratumoral in- TAMs (Fig. 7A) . To assess antitumor efficacy of CpGSTAT3dODN, tumor-bearing mice were injected intratumorally every other day with 5 mg/kg of CpG-STAT3dODN, CpG-scrODN, or PBS. The CpG-STAT3dODN treatment potently reduced RM9 tumor growth, whereas control CpGscrODN had no effect on these aggressive tumors (Fig. 7B) . The therapeutic effect of this strategy is likely 2-pronged and results from targeting both TLR9 + cancer cells, as well as tumor-associated myeloid cells, suggesting therapeutic potential of this strategy for targeting TLR9/LIF/STAT3 signaling in the prostate TME. Taken together, these findings confirm the feasibility of using oligonucleotide therapeutics to target immunosuppressive crosstalk in the TME for prostate cancer therapy. 
DISCUSSION
Growing evidence underscores the role of chronic inflammation in increasing the risk of high-grade prostate cancer [27] [28] [29] . Our results demonstrate that proinflammatory TLR9 signaling intrinsic to prostate cancer cells provides tumors with a direct survival advantage, as we have reported recently [13] and also contributes to the generation of tolerogenic TME. Such an unexpected role of the innate immune receptor in cancer cells seems to rely on the recruitment and the enhanced immunosuppressive activity of PMN-MDSCs. Our study identified LIF, an IL-6-type cytokine, as a mediator of STAT3 signaling and the communication between prostate cancer cells and MDSCs in both human and mouse systems.
A high serum level of LIF has been reported in patients with nasopharyngeal carcinoma cancer [30] and a cancer genomics database (cBioPortal; http://www.cbioportal.org/) indicates that LIF expression is amplified primarily in neuroendocrine prostate cancer (;6%), followed by ovarian, lung, and bladder cancers. Downstream LIFR signaling promotes tumor initiation, progression, metastasis by inducing epithelial-mesenchymal transition (EMT) [31] , and the dormancy of bone marrow metastases in breast cancer [32] . Although the oncogenic activity of LIF in different solid tumors has been described, the role of this cytokine in tumorinduced immunosuppression remains largely unexplored. In a single study, LIF and IL-6 were found in ovarian cancer ascites and induced differentiation of monocytes into immunosuppressive M2-type TAMs [33] . We have demonstrated that cancer cell-intrinsic TLR9 signaling induces LIF secretion, which then promotes the accumulation and tolerogenic activity of PMN-MDSCs in the prostate TME in mice. In addition to LIF, TLR9 signaling induced expression of Csf2 (GM-CSF), a growth factor that promotes neutrophil expansion and proliferation [34] , and Cxcl10 (IP-10), a chemoattractant for myeloid cells, such as monocytes and Mfs [35] . Therefore, it is likely that LIF cooperates with other soluble mediators to orchestrate the accumulation and activation of MDSCs in the prostate TME. Our analysis of blood samples derived from patients with prostate cancer indicated that LIFR is specifically upregulated on PMN-MDSCs in comparison to other myeloid cells in circulation. The PMN-MDSCs consistently showed high sensitivity to LIF-mediated STAT3 activation and augmented immunosuppressive activity. Previous studies in numerous mouse tumor models, including prostate cancers, suggested the role of CXC chemokines, sphingosine-1-phosphate or S100A8 and -A9 calcium-binding proteins as chemoattractants for neutrophils and PMN-MDSCs [22, 36, 37] . LIF-dependent STAT3 activation may enhance PMN-MDSC recruitment to the tumor site, at least partly through the upregulation of S100A8 and -A9. Altogether, our findings indicate that LIF could play multiple roles in promoting recruitment and tolerogenic activity of PMN-MDSCs in human and mouse prostate cancers, which will be explored in our further studies.
LIF and IL-6 share common IL-6Rb subunit (gp130), which upon ligand binding, activates the receptor-associated JAKs and induces tyrosine-phosphorylation of STAT3 [9] . Prior studies implicated IL-6 in promoting tumor progression to an aggressive, hormone-independent/CRPC phenotype [13, 38, 39] . The IL-6-induced STAT3 signaling was responsible for promoting survival and tumorigenic potential of prostate cancer cells, but it can also stimulate proangiogenic and immunosuppressive activity of tumor-associated myeloid cells [6, 13] . At the same time, the source of IL-6 in the prostate TME remains unclear. The recent report of a comprehensive immunohistochemical analysis of human prostate tumor specimens demonstrated that IL-6 mRNA and protein expression are rarely detectable in cancer cells [40] . In contrast, IL-6 expression was pronounced in tumor-infiltrating myeloid cells, which suggested paracrine mechanism of IL-6-mediated STAT3 activation in cancer cells [40] . The findings in our current study suggest that both human and mouse TLR9 + prostate cancer cells expressed significantly higher levels of LIF than any other IL-6-type cytokine (Fig. 3A) . This intriguing observation indicates that LIF plays the major role in mediating signaling between cancer cells and myeloid cells in the prostate TME.
STAT3 is a master regulator of tumor immunosuppression, at least partly through the control of MDSC expansion and Cy3 after single intratumoral injection. CpG-STAT3dODN
Cy3 (5 mg/kg) was injected into RM9 tumors. The uptake by tumor-infiltrating T cells, TAMs, and M-and PMN-MDSCs was evaluated using flow cytometry (n = 4). (B) Local treatment using CpG-STAT3-dODN but not control CpG-scrODN (5 mg/kg, every other day; n = 5) results in RM9 tumor growth inhibition in mice. Data are means 6 SEM. *P , 0.05; **P , 0.01. suppressor activity. The potential for a 2-pronged antitumor effect, direct cytotoxicity against cancer cells and immune activation, make STAT3 an attractive molecular target. However, targeting STAT3 proved challenging because of a plethora of upstream STAT3 activators and potential toxicities. The antibodymediated neutralization of protein mediators in the TME, such as LIF, is likely to have limited antitumor efficacy because of multiplicity of immunosuppressive signals. Thus, we recently developed a strategy to block STAT3 activation in TLR9 + prostate cancers and in the tumor-associated immune cells by conjugating TLR9 ligand to the CpG-STAT3dODN, which competitively binds to the DNA binding domain of the STAT3 dimer [26] . Although CpGSTAT3dODN was originally shown to have efficacy against myeloid leukemia models, our current study underscores the potential to use this strategy to disrupt the immunosuppressive microenvironment in prostate tumors. The therapeutic effect of CpG-STAT3dODN is most likely 2-pronged and results from targeting both TLR9 + cancer cells and tumor-associated myeloid cells. CpG-STAT3dODN is currently undergoing investigational new-drug-enabling studies for immunotherapy of hematologic malignancies. Our results underscore the potential of using this strategy to overcome immunosuppressive effects of MDSCs in patients with advanced prostate cancers. Our study describes a new molecular mechanism linking inflammatory signals downstream of TLR9 to increased tolerogenic activity in the prostate TME, suggesting therapeutic potential in the targeting of the TLR9/LIF/STAT3 signaling axis.
